Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of 22.8%.

-- Stick with investing in the AI revolution, the space revolution and the autonomous-vehicle revolution, as they will radically change the world for the better and are among the most likely trends to ...

As the Chinese society ages, China not only loses its comparative advantage in labor but also faces a severe pension funding ...

A new study reveals the rising burden of liver cancer, highlighting the significant impact of metabolic risk factors like obesity, in addition to viral hepatitis.

Liver cancer is a leading cause of cancer-related deaths worldwide, with distinct geographic patterns in its incidence.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The experts note that mixing fresh water with salt water could reduce acidity and enhance nutrient absorption in the ...

Undoubtedly, after years of neglect, bronchiectasis has become a focus of respiratory research, largely thanks to the establishment of various bronchiectasis registries. Baseline data from registries ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China. The lead ...

The likely aim of China’s fiscal push is to bolster the confidence of households, according to Mr Zook. The more of their ...